Open Access iconOpen Access

REVIEW

crossmark

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas

ASPASIA MANTA1, SPYRIDON KAZANAS2, STEFANOS KARAMAROUDIS3, HELEN GOGAS2, DIMITRIOS C. ZIOGAS2,*

1 Endocrine Unit, Second Department of Internal Medicine Propaedeutic & Research Institute, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, 12461, Greece
2 First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, 11527, Greece
3 Department of Obstetrics & Gynecology, General Hospital of Elefsina Thriassio, Elefsina, 19600, Greece

* Corresponding Author: Dimitrios C. Ziogas, email

Oncology Research 2022, 30(5), 211-219. https://doi.org/10.32604/or.2022.026913

Abstract

Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the expression and functionality of coding gene products are altered following the histone acetylation and deacetylation. These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options. Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis and differentiation, and their mechanism of action mainly depends on the type of cancer. Currently, five HDACis have been approved for the treatment of several hematological malignancies (e.g., T-cell lymphoma subtypes and multiple myeloma); while, many of them are tested for further therapeutic indications in solid tumors (e.g., colorectal, thyroid, breast, lung and pancreatic cancer). Herein, we review the literature and gather all available evidence, from in vitro and in vivo data to clinical trial results, that recognizes the antitumor activity of HDACis on pheochromocytomas and paragangliomas; and supports their clinical implementation in the treatment of these rare neuroendocrine tumors at metastatic setting.

Keywords


Cite This Article

APA Style
MANTA, A., KAZANAS, S., KARAMAROUDIS, S., GOGAS, H., ZIOGAS, D.C. (2022). Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas. Oncology Research, 30(5), 211-219. https://doi.org/10.32604/or.2022.026913
Vancouver Style
MANTA A, KAZANAS S, KARAMAROUDIS S, GOGAS H, ZIOGAS DC. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas. Oncol Res. 2022;30(5):211-219 https://doi.org/10.32604/or.2022.026913
IEEE Style
A. MANTA, S. KAZANAS, S. KARAMAROUDIS, H. GOGAS, and D.C. ZIOGAS "Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas," Oncol. Res., vol. 30, no. 5, pp. 211-219. 2022. https://doi.org/10.32604/or.2022.026913



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1438

    View

  • 706

    Download

  • 1

    Like

Share Link